Navigation Links
Advanced Life Sciences Announces Filing of Shelf Registration Statement
Date:4/8/2009

CHICAGO, April 8 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company developing cethromycin, a novel once-a-day antibiotic, to treat respiratory tract infections and to combat bioterror threats, announced today that it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission ("SEC"). If and when the shelf registration statement is declared effective by the SEC, it will allow the Company to raise capital from time to time through the sale of common stock, preferred stock and/or equity warrants. While the aggregate amount of securities registered on the shelf registration statement is $35 million, the Company's ability to sell securities under the shelf registration statement in any given 12-month period is subject to certain SEC volume limitations relative to its non-affiliated market cap.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

"We have filed a shelf registration statement with SEC to allow the Company to access working capital in increments that are sensitive to shareholder dilution over the three-year term of the shelf," stated Michael Flavin, the Company's chairman and chief executive officer. "The flexibility of the registration statement will provide us with an efficient means to access capital as favorable market opportunities present themselves."

Any future offering and its specific terms will be subject to prevailing market conditions. An offering of securities covered by the shelf registration statement will be made only by means of a written prospectus and prospectus supplement. The Company currently intends to use the proceeds from any offerings under the registration statement for a variety of purpose
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
2. METTLER TOLEDO and AAPS: Utilization of Process Modeling and Advanced Process Control in QbD based Drug Development and Manufacturing
3. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
4. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
5. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
6. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
7. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
8. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
9. Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee
10. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
11. Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... leading provider of room-temperature biosample transport, storage and ... 3.2, the newest version of its software for ... include a strategic licensing model that enables GenConnect ... as well as a new customer licensing model ...
... Crystal Research Associates, LLC announced today that it ... Biotech, Inc. The full 56-page report can be found ... Biotech" or "the Company") is a closely held pharmaceutical ... novel cancer therapeutics. Following a technology spinout from Bayer ...
... Conference Call and Webcast to FollowTHE WOODLANDS, Texas, April ... ) will release its first quarter 2009 financial results ... open. Lexicon management will hold a conference call ... for first quarter 2009 at 11:00 a.m. Eastern Time ...
Cached Biology Technology:GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 2GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 3Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009 2
(Date:9/18/2014)... New research has found clownfish larvae can swim up to ... better able to cope with environmental change. , Clownfish spend ... anemone but as babies they must wander the open ocean, ... of Excellence for Coral Reef Studies (Coral CoE) at James ... they go, but now we,ve been given a rare glimpse ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
(Date:9/17/2014)... in 2000 as an EC-FP5 four-year project, delivering its ... progress and successful participations in several EC projects, as ... Network project (EU BON), to increase the general ... to extend the general dissemination of the Fauna Europaea ... has applied its novel e-Publishing tools to prepare data ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... San Francisco A human monoclonal antibody developed ... (UMMS) given to patients with chronic hepatitis C virus ... for at least a week after transplant and delayed ... double-blind, placebo-controlled, phase 2 study were presented this week ...
... the nature of crowds playing Foldit called some strategies ... methods already used by protein scientists., Gamers made headlines ... central to research on AIDS. Today, in a ... National Academy of Sciences, University of Washington researchers ...
... CORONA, Calif., Nov. 7, 2011 AVT, Inc. (formerly ... partnered with MedBox to provide a new line of ... Fingerprint Recognition System. This new system provides ... and verification of the customer is critical. ...
Cached Biology News:Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3Paper uncovers power of Foldit gamers' strategies 2Paper uncovers power of Foldit gamers' strategies 3AVT Partners with MedBox to Provide New Biometric Fingerprint Recognition for Secure Automated Retailing 2
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
Request Info...
... Electron RapidStak provides valuable walk-away time and ... buffer nest technology for parallel processing of ... fast, reliable automation for any laboratory in ... The RapidStak can be set-up within minutes ...
... Benzonase Nuclease is a genetically engineered endonuclease. ... DNA and RNA while having no proteolytic ... range of conditions and possesses an exceptionally ... nucleic acids from recombinant proteins, its use ...
Biology Products: